Infanrix-Ipv (Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxid)

The pertussis toxoid is an inactivated form of the pertussis toxin that cannot cause disease. When adsorbed onto aluminium hydroxide, it acts as an antigen that stimulates the immune system to produce specific antibodies. These antibodies neutralise the toxin and help the body recognise and fight the actual pertussis bacteria if encountered.

The dose of Infanrix-Ipv is determined by the prescribing health professional according to national immunisation guidelines. Typically, it is given as a single intramuscular injection at specific ages within the infant vaccination schedule, with booster doses administered later as recommended.

Safety data for Infanrix-Ipv in pregnant women are limited, and it is generally not recommended unless the potential benefits outweigh any theoretical risks. Breastfeeding is not a contraindication; the vaccine can be administered to a lactating mother, but the infant should receive the vaccine directly according to the standard schedule.

To order Infanrix-Ipv, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, cold‑chain shipping details and any necessary import documentation.

Infanrix-Ipv contains both pertussis toxoid and pertactin antigens adsorbed on aluminium hydroxide, offering a broad immune response. Compared with monovalent pertussis vaccines, it may provide enhanced protection due to the additional pertactin component. However, reactogenicity can be slightly higher, which is typical for combination vaccines.

Infanrix-Ipv must be stored in a refrigerated environment between 2 °C and 8 °C. It should be kept in its original packaging to protect from light, and must never be frozen or shaken. If the cold chain is broken, the vaccine should be discarded according to local regulations.

Infanrix-Ipv is given as an intramuscular injection, usually into the anterolateral thigh of infants or the deltoid muscle of older children. The injection is performed by a qualified health professional using aseptic technique, and the site should be observed for any immediate adverse reactions.

The most serious risks, although rare, include severe allergic reactions such as anaphylaxis, febrile seizures, and persistent high fever that may require medical evaluation. Immediate medical attention is essential if signs of anaphylaxis (e.g., difficulty breathing, swelling of the face) occur after vaccination.

Infanrix-Ipv is contraindicated in individuals with a known severe allergy to any component of the vaccine, including the pertussis toxoid, pertactin or aluminium hydroxide. It should also be avoided in persons who have experienced a previous severe reaction to a pertussis‑containing vaccine. Consultation with a healthcare provider is advised for any uncertainty.